Suppr超能文献

补充氧疗抗肿瘤作用的免疫机制

Immunological mechanisms of the antitumor effects of supplemental oxygenation.

作者信息

Hatfield Stephen M, Kjaergaard Jorgen, Lukashev Dmitriy, Schreiber Taylor H, Belikoff Bryan, Abbott Robert, Sethumadhavan Shalini, Philbrook Phaethon, Ko Kami, Cannici Ryan, Thayer Molly, Rodig Scott, Kutok Jeffrey L, Jackson Edwin K, Karger Barry, Podack Eckhard R, Ohta Akio, Sitkovsky Michail V

机构信息

New England Inflammation and Tissue Protection Institute, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA.

Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.

出版信息

Sci Transl Med. 2015 Mar 4;7(277):277ra30. doi: 10.1126/scitranslmed.aaa1260.

Abstract

Antitumor T cells either avoid or are inhibited in hypoxic and extracellular adenosine-rich tumor microenvironments (TMEs) by A2A adenosine receptors. This may limit further advances in cancer immunotherapy. There is a need for readily available and safe treatments that weaken the hypoxia-A2-adenosinergic immunosuppression in the TME. Recently, we reported that respiratory hyperoxia decreases intratumoral hypoxia and concentrations of extracellular adenosine. We show that it also reverses the hypoxia-adenosinergic immunosuppression in the TME. This, in turn, stimulates (i) enhanced intratumoral infiltration and reduced inhibition of endogenously developed or adoptively transfered tumor-reactive CD8 T cells, (ii) increased proinflammatory cytokines and decreased immunosuppressive molecules, such as transforming growth factor-β (TGF-β), (iii) weakened immunosuppression by regulatory T cells, and (iv) improved lung tumor regression and long-term survival in mice. Respiratory hyperoxia also promoted the regression of spontaneous metastasis from orthotopically grown breast tumors. These effects are entirely T cell- and natural killer cell-dependent, thereby justifying the testing of supplemental oxygen as an immunological coadjuvant to combine with existing immunotherapies for cancer.

摘要

在缺氧且细胞外富含腺苷的肿瘤微环境(TME)中,抗肿瘤T细胞会被A2A腺苷受体避开或抑制。这可能会限制癌症免疫疗法的进一步发展。因此,需要有现成且安全的治疗方法来削弱TME中的缺氧 - A2 - 腺苷能免疫抑制作用。最近,我们报道呼吸性高氧可降低肿瘤内的缺氧程度和细胞外腺苷浓度。我们还发现,它能逆转TME中的缺氧 - 腺苷能免疫抑制作用。这反过来又会刺激:(i)增强肿瘤内浸润,并减少对内源性产生或过继转移的肿瘤反应性CD8 T细胞的抑制;(ii)增加促炎细胞因子,并减少免疫抑制分子,如转化生长因子 - β(TGF - β);(iii)削弱调节性T细胞的免疫抑制作用;以及(iv)改善小鼠肺部肿瘤的消退和长期生存。呼吸性高氧还促进了原位生长的乳腺肿瘤自发转移灶的消退。这些效应完全依赖于T细胞和自然杀伤细胞,因此有理由将补充氧气作为一种免疫佐剂进行测试,以便与现有的癌症免疫疗法联合使用。

相似文献

引用本文的文献

6
Insights from Clinical Trials on A Adenosine Receptor Antagonists for Cancer Treatment.A腺苷受体拮抗剂用于癌症治疗的临床试验见解。
ACS Pharmacol Transl Sci. 2025 May 2;8(6):1498-1512. doi: 10.1021/acsptsci.5c00057. eCollection 2025 Jun 13.
8
Bioactive polydopamine nanomedicines-assisted cancer immunotherapy.生物活性聚多巴胺纳米药物辅助癌症免疫治疗
Mater Today Bio. 2025 May 13;32:101864. doi: 10.1016/j.mtbio.2025.101864. eCollection 2025 Jun.
9
Application of radiomics in lung immuno-oncology.放射组学在肺部免疫肿瘤学中的应用。
Precis Radiat Oncol. 2023 Apr 4;7(2):128-136. doi: 10.1002/pro6.1191. eCollection 2023 Jun.
10
Mechanistic insights into resistance mechanisms to T cell engagers.对T细胞衔接器耐药机制的机制性见解。
Front Immunol. 2025 Apr 22;16:1583044. doi: 10.3389/fimmu.2025.1583044. eCollection 2025.

本文引用的文献

1
Immune modulation for cancer therapy.用于癌症治疗的免疫调节。
Br J Cancer. 2014 Dec 9;111(12):2214-9. doi: 10.1038/bjc.2014.348. Epub 2014 Sep 11.
4
Targeting cancer-derived adenosine: new therapeutic approaches.靶向肿瘤源性腺苷:新的治疗方法。
Cancer Discov. 2014 Aug;4(8):879-88. doi: 10.1158/2159-8290.CD-14-0341. Epub 2014 Jul 17.
7
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.A2A 受体阻断剂能有效抑制 CD73+肿瘤的转移。
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14711-6. doi: 10.1073/pnas.1308209110. Epub 2013 Aug 20.
10
Regulation of ligands for the NKG2D activating receptor.NKG2D 激活受体配体的调节。
Annu Rev Immunol. 2013;31:413-41. doi: 10.1146/annurev-immunol-032712-095951. Epub 2013 Jan 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验